中药调控氧化应激治疗胆汁淤积性肝损伤的机制及临床应用

唐银佩; 佘琳静; 朱正望; 王兵; 朱平生

doi:10.12449/JCH260534

中药调控氧化应激治疗胆汁淤积性肝损伤的机制及临床应用

DOI: 10.12449/JCH260534

1.
河南中医药大学第一临床医学院，郑州 450046
2.
河南中医药大学第三附属医院消化科，郑州 450008
3.
上海交通大学医学院附属第六人民医院中医科，上海 200240

基金项目:

国家自然科学基金 (82074340);

河南省“双一流”创建学科中医学科学研究专项 (HSRP-DFCTCM-2023-1-19);

上海市“科学与创新行动计划”自然科学基金面上项目 (23ZR1448400)

利益冲突声明：本研究不存在任何利益冲突。

作者贡献声明：唐银佩负责归纳文献、撰写论文；佘琳静和朱正望参与查阅整理文献资料；王兵负责拟定写作思路；朱平生指导撰写文章并最后定稿。

详细信息

通信作者:
朱平生， zps@hactcm.edu.cn （ORCID： 0009-0002-1678-392X）

计量
- 文章访问数: 8
- HTML全文浏览量: 1
- PDF下载量: 0
- 被引次数: 0
出版历程
- 收稿日期: 2025-08-21
- 录用日期: 2025-10-13
- 出版日期: 2026-05-20

Mechanism and clinical application of traditional Chinese medicine in treatment of cholestatic liver injury by regulating oxidative stress

1.
The First Clinical Medical College of Henan University of Chinese Medicine，Zhengzhou 450046，China
2.
Department of Gastroenterology，The Third Affiliated Hospital of Henan University of Chinese Medicine，Zhengzhou 450008，China
3.
Department of Traditional Chinese Medicine，Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine，Shanghai 200240，China

Research funding:

National Natural Science Foundation of China (82074340);

Special Project for Scientific Research of Henan Province’s “Double First-Class” Creation Discipline of Traditional Chinese Medicine (HSRP-DFCTCM-2023-1-19);

Shanghai Science and Innovation Action Plan Natural Science Foundation General Project (23ZR1448400)

More Information

Corresponding author: ZHU Pingsheng， zps@hactcm.edu.cn （ORCID： 0009-0002-1678-392X）

摘要

摘要: 胆汁淤积性肝损伤（CLI）是由多种原因导致胆汁酸在体内异常蓄积引起的肝脏病变，若不及时干预，可逐步进展为肝纤维化、肝硬化、肝衰竭，甚至死亡。研究表明，通过调控氧化应激可减轻脂质过氧化和细胞损伤，进而抑制炎症与细胞凋亡。近年来，中药活性成分及复方在调控氧化应激治疗CLI方面取得积极进展。本文系统总结了中药基于氧化应激调控治疗CLI的作用机制及临床应用研究现状。
- 胆汁淤积 /
- 氧化性应激 /
- 中药
Abstract: Cholestatic liver injury （CLI） is a hepatic disorder characterized by the abnormal accumulation of bile acids in the body due to various etiologies， and without timely intervention， it can progress to liver fibrosis， liver cirrhosis， and liver failure and even lead to death. Studies have shown that modulating oxidative stress can alleviate lipid peroxidation and cellular damage， thereby suppressing inflammation and cell apoptosis. In recent years， remarkable progress has been made regarding the active components and compound prescriptions of traditional Chinese medicine in the treatment of CLI by regulating oxidative stress. This article systematically reviews the current status of research on the mechanism of action and clinical application of traditional Chinese medicine in the treatment of CLI by regulating oxidative stress.
- Cholestasis /
- Oxidative Stress /
- Traditional Chinese Drugs

HTML全文

注： BA，胆汁酸；LPS，脂多糖；TLR4，Toll样受体4；ROS/RNS，活性氧/活性氮；Keap1，Kelch样环氧氯丙烷相关蛋白1；Nrf2，核转录因子红系2相关因子2；ARE，抗氧化反应元件；HO-1，血红素氧合酶-1；SOD，超氧化物歧化酶；GSH，还原型谷胱甘肽；GSH-Px，谷胱甘肽过氧化物酶；Egr-1，早期生长反应蛋白1；CLI，胆汁淤积性肝损伤；OS，氧化应激。

图 1 OS机制及其与CLI关系

Figure 1. OS mechanisms and their relationship with CLI

下载: 全尺寸图片幻灯片

参考文献(48)

[1]	HILSCHER MB, KAMATH PS, EATON JE. Cholestatic liver diseases: A primer for generalists and subspecialists[J]. Mayo Clin Proc, 2020, 95( 10): 2263- 2279. DOI: 10.1016/j.mayocp.2020.01.015.
[2]	WU HH, CHEN CB, ZIANI S, et al. Fibrotic events in the progression of cholestatic liver disease[J]. Cells, 2021, 10( 5): 1107. DOI: 10.3390/cells10051107.
[3]	Chinese Society of Hepatology, Chinese Medical Association. Guideline on the management of cholestasis liver diseases[J]. J Clin Hepatol, 2022, 38( 1): 62- 69. DOI: 10.3760/cma.j.cn112138-20211112-00795. 中华医学会肝病学分会. 胆汁淤积性肝病管理指南(2021年)[J]. 临床肝胆病杂志, 2022, 38( 1): 62- 69. DOI: 10.3760/cma.j.cn112138-20211112-00795.
[4]	RINI SS, WIBAWA IDN. Evaluation and management of chronic cholestatic liver diseases[J]. Middle East J Dig Dis, 2023, 15( 3): 148- 155. DOI: 10.34172/mejdd.2023.336.
[5]	ODENWALD MA, PAUL S. Viral hepatitis: Past, present, and future[J]. World J Gastroenterol, 2022, 28( 14): 1405- 1429. DOI: 10.3748/wjg.v28.i14.1405.
[6]	FUJITA N, YASUDA I, ENDO I, et al. Evidence-based clinical practice guidelines for cholelithiasis 2021[J]. J Gastroenterol, 2023, 58( 9): 801- 833. DOI: 10.1007/s00535-023-02014-6.
[7]	POLYZOS SA, KOUNTOURAS J, MANTZOROS CS. Obeticholic acid for the treatment of nonalcoholic steatohepatitis: Expectations and concerns[J]. Metabolism, 2020, 104: 154144. DOI: 10.1016/j.metabol.2020.154144.
[8]	RUDIC JS, POROPAT G, KRSTIC MN, et al. Ursodeoxycholic acid for primary biliary cirrhosis[J]. Cochrane Database Syst Rev, 2012, 2012( 12): CD000551. DOI: 10.1002/14651858.cd000551.pub3.
[9]	TERRAULT NA, FRANCOZ C, BERENGUER M, et al. Liver transplantation 2023: Status report, current and future challenges[J]. Clin Gastroenterol Hepatol, 2023, 21( 8): 2150- 2166. DOI: 10.1016/j.cgh.2023.04.005.
[10]	XU FP, ZHANG H, CHEN JM, et al. Recent progress on the application of compound formulas of traditional Chinese medicine in clinical trials and basic research in vivo for chronic liver disease[J]. J Ethnopharmacol, 2024, 321: 117514. DOI: 10.1016/j.jep.2023.117514.
[11]	JOMOVA K, RAPTOVA R, ALOMAR SY, et al. Reactive oxygen species, toxicity, oxidative stress, and antioxidants: Chronic diseases and aging[J]. Arch Toxicol, 2023, 97( 10): 2499- 2574. DOI: 10.1007/s00204-023-03562-9.
[12]	ZHENG DD, LIU J, PIAO HL, et al. ROS-triggered endothelial cell death mechanisms: Focus on pyroptosis, parthanatos, and ferroptosis[J]. Front Immunol, 2022, 13: 1039241. DOI: 10.3389/fimmu.2022.1039241.
[13]	ABRESCIA P, TREPPICCIONE L, ROSSI M, et al. Modulatory role of dietary polyunsaturated fatty acids in Nrf2-mediated redox homeostasis[J]. Prog Lipid Res, 2020, 80: 101066. DOI: 10.1016/j.plipres.2020.101066.
[14]	LI KX, DENG Z, LEI CR, et al. The role of oxidative stress in tumorigenesis and progression[J]. Cells, 2024, 13( 5): 441. DOI: 10.3390/cells13050441.
[15]	FLOHÉ L, TOPPO S, ORIAN L. The glutathione peroxidase family: Discoveries and mechanism[J]. Free Radic Biol Med, 2022, 187: 113- 122. DOI: 10.1016/j.freeradbiomed.2022.05.003.
[16]	BASIGLIO CL, CROCENZI FA, SÁNCHEZ POZZI EJ, et al. Oxidative stress and localization status of hepatocellular transporters: Impact on bile secretion and role of signaling pathways[J]. Antioxid Redox Signal, 2021, 35( 10): 808- 831. DOI: 10.1089/ars.2021.0021.
[17]	VENDITTI P, DI MEO S. The role of reactive oxygen species in the life cycle of the mitochondrion[J]. Int J Mol Sci, 2020, 21( 6): 2173. DOI: 10.3390/ijms21062173.
[18]	ONG G, LOGUE SE. Unfolding the interactions between endoplasmic reticulum stress and oxidative stress[J]. Antioxidants, 2023, 12( 5): 981. DOI: 10.3390/antiox12050981.
[19]	HU WD, HE ZK, DU L, et al. Biomarkers of oxidative stress in broiler chickens attacked by lipopolysaccharide: A systematic review and meta-analysis[J]. Ecotoxicol Environ Saf, 2023, 266: 115606. DOI: 10.1016/j.ecoenv.2023.115606.
[20]	CHEN J, ZHANG SJ. The role of inflammation in cholestatic liver injury[J]. J Inflamm Res, 2023, 16: 4527- 4540. DOI: 10.2147/jir.s430730.
[21]	PAGEL JI, DEINDL E. Disease progression mediated by egr-1 associated signaling in response to oxidative stress[J]. Int J Mol Sci, 2012, 13( 10): 13104- 13117. DOI: 10.3390/ijms131013104.
[22]	ZHUANG HC, XU R, WANG T, et al. Effects of picroside II on cholestatic liver injury in rats induced by bile duct ligation[J]. Drug Eval Res, 2018, 41( 10): 1786- 1790. DOI: 10.7501/j.issn.1674-6376.2018.10.007. 庄辉传, 许锐, 王涛, 等. 胡黄连苷Ⅱ对大鼠胆管结扎胆汁淤积的改善作用[J]. 药物评价研究, 2018, 41( 10): 1786- 1790. DOI: 10.7501/j.issn.1674-6376.2018.10.007.
[23]	TOKAÇ M, TANER G, AYDıN S, et al. Protective effects of curcumin against oxidative stress parameters and DNA damage in the livers and kidneys of rats with biliary obstruction[J]. Food Chem Toxicol, 2013, 61: 28- 35. DOI: 10.1016/j.fct.2013.01.015.
[24]	PAN PH, LIN SY, WANG YY, et al. Protective effects of rutin on liver injury induced by biliary obstruction in rats[J]. Free Radic Biol Med, 2014, 73: 106- 116. DOI: 10.1016/j.freeradbiomed.2014.05.001.
[25]	ZHANG CL. Protective mechanism and pharmacokinetics of baicalin in rats with estrogen-induced intrahepatic cholestasis[D]. Wuhan: Huazhong University of Science and Technology, 2018. 张程亮. 黄芩苷在雌激素诱导肝内胆汁淤积大鼠中的干预机制和药动学研究[D]. 武汉: 华中科技大学, 2018.
[26]	SONG DD. Study on the mechanism of action of crocin I against intrahepatic cholestatic liver injury[D]. Nanchang: Jiangxi University of Traditional Chinese Medicine, 2022. 宋丹丹. 西红花苷Ⅰ抗IC型肝损伤的作用机制研究[D]. 南昌: 江西中医药大学, 2022.
[27]	WU T, CHANG MJ, XU YJ, et al. Protective effect of Calculus bovis sativus on intrahepatic cholestasis in rats induced by α-naphthylisothiocyanate[J]. Am J Chin Med, 2013, 41( 6): 1393- 1405. DOI: 10.1142/s0192415x13500936.
[28]	ONALAN AK, TUNCAL S, KILICOGLU S, et al. Effect of sılymarın on oxıdatıve stress and lıver hıstopathology ın experımental obstructıve jaundıce model[J]. Acta Cir Bras, 2016, 31( 12): 801- 806. DOI: 10.1590/s0102-865020160120000004.
[29]	ZHAO YL, ZHOU GD, WANG JB, et al. Paeoniflorin protects against ANIT-induced cholestasis by ameliorating oxidative stress in rats[J]. Food Chem Toxicol, 2013, 58: 242- 248. DOI: 10.1016/j.fct.2013.04.030.
[30]	WANG L, CAO F, ZHU LL, et al. Andrographolide impairs alpha-naphthylisothiocyanate-induced cholestatic liver injury in vivo[J]. J Nat Med, 2019, 73( 2): 388- 396. DOI: 10.1007/s11418-018-01275-3.
[31]	SIES H, BERNDT C, JONES DP. Oxidative stress[J]. Annu Rev Biochem, 2017, 86: 715- 748. DOI: 10.1146/annurev-biochem-061516-045037.
[32]	MOROVICZ AP, MAZLOUMI GAVGANI F, JACOBSEN RG, et al. Phosphoinositide 3-kinase signalling in the nucleolus[J]. Adv Biol Regul, 2022, 83: 100843. DOI: 10.1016/j.jbior.2021.100843.
[33]	HU XZ, HUANG YF, ZHANG W. Effect of ammidin on cholestatic hepatitis mice based on PI3K/Akt/GSK-3β signaling pathway[J]. J Guangdong Pharm Univ, 2021, 37( 6): 57- 62. DOI: 10.16809/j.cnki.2096-3653.2021072405. 胡旭中, 黄宜锋, 张伟. 基于PI3K/AKT/GSK-3β信号通路探讨白芷乙素对胆汁淤积性肝炎小鼠的作用[J]. 广东药科大学学报, 2021, 37( 6): 57- 62. DOI: 10.16809/j.cnki.2096-3653.2021072405.
[34]	MIAO ZZ, WU SM, CHEN C, et al. Protective mechanism of resveratrol on kidney injury of obstructive jaundice in rat[J]. Chin J Bases Clin Gen Surg, 2015, 22( 2): 172- 176. DOI: 10.7507/1007-9424.20150047. 苗志钊, 邬善敏, 陈辰, 等. 白藜芦醇对梗阻性黄疸大鼠肾损害的保护机制[J]. 中国普外基础与临床杂志, 2015, 22( 2): 172- 176. DOI: 10.7507/1007-9424.20150047.
[35]	WANG WC, MA YP, WANG M, et al. Therapeutic effect of emodin on cholestatic liver injury in mice based on CYP7A1/FXR/SHP pathway[J]. Chin J Clin Pharmacol Ther, 2026, 31( 2): 204- 212. DOI: 10.12092/j.issn.1009-2501.2026.02.008. 王玮辰, 马雅萍, 王萌, 等. 基于CYP7A1/FXR/SHP途径探究大黄素对胆汁淤积性肝损伤小鼠的治疗作用[J]. 中国临床药理学与治疗学, 2026, 31( 2): 204- 212. DOI: 10.12092/j.issn.1009-2501.2026.02.008.
[36]	ZHANG Y, HOU WN, SUN Q, et al. Repair of oxidative stress injury and regulation of nuclear factor κB pathway in rats withα-naphthalene isothiocyanate-induced intrahepatic cholestasis by Dahuang Granule prescription[J]. Eval Anal Drug Use Hosp China, 2022, 22( 6): 680- 683. DOI: 10.14009/j.issn.1672-2124.2022.06.011. 张英, 侯伟娜, 孙琦, 等. 大黄免煎颗粒对α-萘异硫氰酸酯诱导的肝内胆汁淤积大鼠氧化应激损伤的修复及核因子κB通路的调节作用研究[J]. 中国医院用药评价与分析, 2022, 22( 6): 680- 683. DOI: 10.14009/j.issn.1672-2124.2022.06.011.
[37]	MICHALAK KP, MICHALAK AZ. Understanding chronic inflammation: Couplings between cytokines, ROS, NO, Ca_i ²⁺, HIF-1α, Nrf2 and autophagy[J]. Front Immunol, 2025, 16: 1558263. DOI: 10.3389/fimmu.2025.1558263.
[38]	CAO L, LI J, HUANG C, et al. Protective effect of Zhizi Bopi decoction on α-naphthylisothiocyanate induced intrahepatic cholestasis in rats[J]. Acta Univ Med Anhui, 2013, 48( 3): 257- 262. 曹璐, 李俊, 黄成, 等. 栀子柏皮汤对α-萘异硫氰酸酯诱导的肝内胆汁淤积大鼠的保护作用[J]. 安徽医科大学学报, 2013, 48( 3): 257- 262.
[39]	YUAN S. Mechanism of Yinchenhao decoction regulating Keap1/Nrf2 pathway to prevent liver injury in rats with dampness heat syndrome of cholestatic liver disease[D]. Jinan: Shandong University of Traditional Chinese Medicine, 2022. 袁顺. 茵陈蒿汤调控Keap1/Nrf2通路防治胆汁淤积性肝病湿热证大鼠肝损伤的作用机制研究[D]. 济南: 山东中医药大学, 2022.
[40]	TAN MA, KANG JH, SHE SF, et al. Effects of Yinzhihuang injection on oxidative stress and FXR gene expression in cholestatic hepatitis rats[J]. J Guangzhou Univ Tradit Chin Med, 2018, 35( 3): 466- 470. DOI: 10.13359/j.cnki.gzxbtcm.2018.03.019. 谭梅傲, 康锦花, 佘世锋, 等. 茵栀黄注射液对胆汁淤积性肝炎大鼠氧化应激反应及FXR基因表达的影响[J]. 广州中医药大学学报, 2018, 35( 3): 466- 470. DOI: 10.13359/j.cnki.gzxbtcm.2018.03.019.
[41]	WANG XF, HU CM, ZHAO Z, et al. Effect and mechanism of Yinchen Wuling Powder on liver function in young rats with cholestasis[J]. Chin J Public Health, 2021, 37( 10): 1521- 1526. DOI: 10.11847/zgggws1132576. 王新芳, 胡晨旻, 赵真, 等. 茵陈五苓散对胆汁淤积幼龄大鼠肝功能保护作用[J]. 中国公共卫生, 2021, 37( 10): 1521- 1526. DOI: 10.11847/zgggws1132576.
[42]	CAO D, CHEN Q, CHEN XL, et al. Effect of sinisan on oxidative stress in cholestatic hepatitis rats based on Nrf2/HO-1 signaling pathway[J]. Chin J Exp Tradit Med Formulae, 2024, 30( 12): 1- 7. DOI: 10.13422/j.cnki.syfjx.20240602. 曹丹, 陈祺, 陈小橹, 等. 基于Nrf2/HO-1信号通路探讨四逆散对胆汁淤积性炎大鼠氧化应激反应的影响[J]. 中国实验方剂学杂志, 2024, 30( 12): 1- 7. DOI: 10.13422/j.cnki.syfjx.20240602.
[43]	LIU BB, YAO JM, YANG QR, et al. The regulation of Nrf2 antioxidant stress response by San-Huang-Chai-Zhu formula for the prevention and treatment of acute intrahepatic cholestasis-induced liver injury[J]. Zhejiang Clin Med J, 2024, 26( 5): 637- 639. 刘彬彬, 姚嘉明, 杨晴柔, 等. 三黄柴术方调控Nrf2抗氧化应激防治急性肝内胆汁淤积性肝损伤[J]. 浙江临床医学, 2024, 26( 5): 637- 639.
[44]	LOU J, ZHAO L, ZHU YJ, et al. Study on protective effect of Chaihu Shugan Powder against liver injury in rats with intrahepatic cholestasis by regulating FXR/Nrf2/ARE pathway[J]. China J Chin Mater Med, 2022, 47( 20): 5610- 5616. DOI: 10.19540/j.cnki.cjcmm.20220519.401. 娄静, 赵雷, 朱岩洁, 等. 柴胡疏肝散调控FXR/Nrf2/ARE通路对肝内胆汁淤积大鼠肝损伤的保护作用研究[J]. 中国中药杂志, 2022, 47( 20): 5610- 5616. DOI: 10.19540/j.cnki.cjcmm.20220519.401.
[45]	AYIZIBA TEH, YANG JH, WANG XM, et al. Effects and mechanism of Hugan buzure formula on intrahepatic cholestatic liver injury in rats[J]. China Pharm, 2023, 34( 16): 1943- 1948. DOI: 10.6039/j.issn.1001-0408.2023.16.05. 阿依孜巴·图尔洪, 杨建华, 王晓梅, 等. 护肝布祖热方对大鼠肝内胆汁淤积性肝损伤的影响及机制[J]. 中国药房, 2023, 34( 16): 1943- 1948. DOI: 10.6039/j.issn.1001-0408.2023.16.05.
[46]	XUN L, LU BJ. Clinical efficacy of danqing granules in acute intrahepatic cholestasis with liver-gallbladder dampness-heat syndrome[J]. Chin J Exp Tradit Med Formulae, 2016, 22( 15): 190- 193. DOI: 10.13422/j.cnki.syfjx.2016150190. 荀蕾, 卢秉久. 疸清颗粒治疗肝胆湿热型急性肝内胆汁淤积症[J]. 中国实验方剂学杂志, 2016, 22( 15): 190- 193. DOI: 10.13422/j.cnki.syfjx.2016150190.
[47]	MA Y. Effect of Lidan Huayu Yunpi Recipe on intrahepatic cholestasis Induced by chronic hepatitis B[J]. Mod J Integr Tradit Chin West Med, 2016, 25( 27): 2992- 2994. DOI: 10.3969/j.issn.1008-8849.2016.27.009. 马瑛. 利胆化瘀运脾方治疗慢性乙型肝炎肝内胆汁淤积疗效观察[J]. 现代中西医结合杂志, 2016, 25( 27): 2992- 2994. DOI: 10.3969/j.issn.1008-8849.2016.27.009.
[48]	ZHU XD, SU CZ, MENG XX, et al. Potential mechanism of compound Danhuang formula in the treatment of cholestatic liver disease of liver-gallbladder dampness-heat pattern[J]. Eval Anal Drug Use Hosp China, 2023, 23( 10): 1195- 1199, 1205. DOI: 10.14009/j.issn.1672-2124.2023.10.009. 朱晓迪, 苏春芝, 孟宪鑫, 等. 探讨复方丹黄方治疗肝胆湿热型胆汁淤积性肝病的潜在作用机制[J]. 中国医院用药评价与分析, 2023, 23( 10): 1195- 1199, 1205. DOI: 10.14009/j.issn.1672-2124.2023.10.009.